Health-related quality of life after pancreatic resection for malignancy

Background Health‐related quality of life (QoL) is of major importance in pancreatic cancer, owing to the limited life expectation. The aim of this prospective longitudinal study was to describe QoL in patients undergoing resection for pancreatic or periampullary malignancy. Methods QoL was measured...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of surgery Vol. 103; no. 3; pp. 257 - 266
Main Authors Heerkens, H. D., Tseng, D. S. J., Lips, I. M., van Santvoort, H. C., Vriens, M. R., Hagendoorn, J., Meijer, G. J., Borel Rinkes, I. H. M., van Vulpen, M., Molenaar, I. Q.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.02.2016
Oxford University Press
Subjects
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Health Status
Humans
Male
Middle Aged
Pancreatectomy - methods
Pancreatectomy - psychology
Pancreatic Neoplasms - psychology
Pancreatic Neoplasms - surgery
Prospective Studies
Quality of Life
Surveys and Questionnaires
Online AccessGet full text

Cover

More Information
Summary:Background Health‐related quality of life (QoL) is of major importance in pancreatic cancer, owing to the limited life expectation. The aim of this prospective longitudinal study was to describe QoL in patients undergoing resection for pancreatic or periampullary malignancy. Methods QoL was measured on a scale of 0–100 in patients who underwent pancreatic resection for malignancy or premalignancy at the University Medical Centre Utrecht before resection, and 1, 3, 6 and 12 months after surgery. Measures consisted of the RAND‐36, the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ‐C30) and the EORTC pancreatic cancer‐specific module (QLQ‐PAN26). Results Between March 2012 and November 2013, 68 consecutive patients with a malignancy (59 patients) or premalignancy (9) were included. Physical role restriction, social and emotional domains showed a significant and clinically relevant deterioration directly after operation in 53 per cent (RAND‐36, P < 0·001), 63 and 78 per cent (QLQ‐C30 and RAND‐36 respectively, P < 0·001) and 37 per cent (RAND‐36, P < 0·001) of patients respectively. Most domains demonstrated recovery to preoperative values or better at 3 months, except for physical functioning. Emotional functioning at 3, 6 and 12 months was better than at baseline (P < 0·001). Symptom scores revealed a deterioration in vitality, pain (P = 0·002), fatigue (P < 0·001), appetite loss (P < 0·001), altered bowel habit (P = 0·001) and side‐effects (P < 0·001) after 1 month. After 3 months, only side‐effects were worse than preoperative values (P < 0·001). Conclusion QoL after pancreatic resection for malignant and premalignant tumours decreased considerably in the early postoperative phase. Full recovery of QoL took up to 6 months after the operation. Quality of life recovers in 6 months
Bibliography:ark:/67375/WNG-CVHTP6DF-T
Fig. S1 Mean(s.d.) scores for RAND-36 questionnaire items at each time point. *P < 0.050 versus baseline (paired t test) Fig. S2 Mean(s.d.) scores for European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire items at each time point. *P < 0.050 versus baseline (paired t test) Fig. S3 Mean(s.d.) scores for European Organization for Research and Treatment of Cancer (EORTC) QLQ-PAN26 questionnaire items at each time point. *P < 0.050 versus baseline (paired t test) Fig. S4 RAND-36 questionnaire results at each time point categorized according to change compared with baseline: clinically relevant improvement, stable or clinically relevant worsening. A change of 10 per cent compared with baseline was considered a clinically relevant change Fig. S5 European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire results at each time point categorized according to change compared with baseline: clinically relevant improvement, stable or clinically relevant worsening. A change of 10 per cent compared with baseline was considered a clinically relevant change Fig. S6 European Organization for Research and Treatment of Cancer (EORTC) QLQ-PAN26 questionnaire results at each time point categorized according to change compared with baseline: clinically relevant improvement, stable or clinically relevant worsening. A change of 10 per cent compared with baseline was considered a clinically relevant change
istex:1A1A5AD86EAAE24CAE93DB7C647EB3DA5F48807B
ArticleID:BJS10032
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0007-1323
1365-2168
DOI:10.1002/bjs.10032